» Articles » PMID: 35846544

Effect of Antiretroviral Therapy on Cardiac Risk Markers in People Living with HIV/AIDS

Overview
Date 2022 Jul 18
PMID 35846544
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Chronic HIV infection and antiretroviral therapy (ART) are the major causes of cardiovascular diseases (CVDs) and mortality in HIV patients. This study was conducted to look upon the effect of ART on CVD risk markers in patients on different ART regimens and ART-naïve patients.

Methods: It was a cross-sectional, observational study done on 120 HIV-infected patients. CV risk markers were assessed and correlated with disease-specific factors within individual subgroups differentiated as Group A (ART naïve), Group B (first-line ART), and Group C (second-line ART). Carotid intimal medial thickness (CIMT) and high-sensitivity C reactive protein (hsCRP) were done to classify cases as having CVD.

Results: CVD risk parameters were found to be significantly higher in cases on ART, as compared to ART-naïve cases. The mean CIMT among cases in Group C, Group B, and Group A was 0.072 ± 0.01 cm, 0.063 ± 0.01 cm, and 0.055 ± 0.01 cm, respectively ( < 0.01). 95%, 65% and 25% cases in Group C, Group B, and Group A, respectively, had high CIMT (>0.06 cm) and were seen to be directly correlated with disease-related factors, i.e., duration of disease and ART, type of ART, and low CD4 cell counts. hsCRP was significantly increased in 65 out of total 120 cases. The mean hsCRP in Group A, Group B, and Group C was 3.69 ± 3.37, 4.21 ± 3.4, and 5.72 ± 3.54 mg/L, respectively ( < 0.01), which corresponds to the high risk of CVD.

Conclusion: CVD risk parameters of CIMT and hsCRP are seen to be higher in patients on ART than ART-naive subjects.

Citing Articles

Direct and indirect cardiovascular and cardiometabolic sequelae of the combined anti-retroviral therapy on people living with HIV.

Batta Y, King C, Cooper F, Johnson J, Haddad N, Boueri M Front Physiol. 2023; 14:1118653.

PMID: 37078025 PMC: 10107050. DOI: 10.3389/fphys.2023.1118653.

References
1.
Samaras K, Wand H, Law M, Emery S, Cooper D, Carr A . Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat.... Diabetes Care. 2006; 30(1):113-9. DOI: 10.2337/dc06-1075. View

2.
De Luca A, de Gaetano Donati K, Colafigli M, Cozzi-Lepri A, De Curtis A, Gori A . The association of high-sensitivity c-reactive protein and other biomarkers with cardiovascular disease in patients treated for HIV: a nested case-control study. BMC Infect Dis. 2013; 13:414. PMC: 3846422. DOI: 10.1186/1471-2334-13-414. View

3.
de Saint Martin L, Vandhuick O, Guillo P, Bellein V, Bressollette L, Roudaut N . Premature atherosclerosis in HIV positive patients and cumulated time of exposure to antiretroviral therapy (SHIVA study). Atherosclerosis. 2005; 185(2):361-7. DOI: 10.1016/j.atherosclerosis.2005.06.049. View

4.
Belcaro G, Nicolaides A, Ramaswami G, Cesarone M, De Sanctis M, Incandela L . Carotid and femoral ultrasound morphology screening and cardiovascular events in low risk subjects: a 10-year follow-up study (the CAFES-CAVE study(1)). Atherosclerosis. 2001; 156(2):379-87. DOI: 10.1016/s0021-9150(00)00665-1. View

5.
Ross A, Rizk N, ORiordan M, Dogra V, El-Bejjani D, Storer N . Relationship between inflammatory markers, endothelial activation markers, and carotid intima-media thickness in HIV-infected patients receiving antiretroviral therapy. Clin Infect Dis. 2009; 49(7):1119-27. PMC: 3895473. DOI: 10.1086/605578. View